MiNK Therapeutics announced new preclinical data from its iNKT cell therapy programs, agenT-797 and PRAME-TCR, at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting on November 7, 2024. The data indicated that agenT-797 can be combined with next-generation immune checkpoint inhibitors and bispecific engagers to improve anti-cancer responses.
Dr. Marc Van Dijk, CSO at MiNK, stated that agenT-797 demonstrates important immune modulating effects, enhancing the activity of other immune therapies. The PRAME-TCR iNKT program was highlighted as a novel and differentiated approach for treating PRAME positive solid tumors.
These findings suggest that iNKT cell therapies have the potential to offer meaningful advancements in cancer treatment by targeting the tumor microenvironment without requiring lymphodepletion or HLA-matching. The company aims to provide durable, scalable, and accessible solutions for patients with limited treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.